Proof of concept for an improved twice-daily controlled-release formulation of morphine.

Egalet a/s has demonstrated proof of concept for an improved twice-daily controlled-release formulation of morphine. Successful studies with the new formulation based on the patented Egalet technology show pain relief comparable with conventional morphine sustained release products on the market, and at the same time a tendency towards fewer adverse effects is seen in the group of patients receiving the Egalet formulation. Plasma measurements have also demonstrated fewer fluctuations in the concentrations of morphine in the Egalet treated group. The new morphine formulation is developed by Egalet a/s and utilises the Egalet zero order release technology referred to as 2KTM.

The release as fetched from its publisher. egalet.com ↗